Cargando…

MDM2 SNP309 and SNP285 Act as Negative Prognostic Markers for Non-small Cell Lung Cancer Adenocarcinoma Patients

Objectives: Two functional polymorphisms in the MDM2 promoter region, SNP309T>G and SNP285G>C, have been shown to impact MDM2 expression and cancer risk. Currently available data on the prognostic value of MDM2 SNP309 in non-small cell lung cancer (NSCLC) is contradictory and unavailable for S...

Descripción completa

Detalles Bibliográficos
Autores principales:	Deben, Christophe, Op de Beeck, Ken, Van den Bossche, Jolien, Jacobs, Julie, Lardon, Filip, Wouters, An, Peeters, Marc, Van Camp, Guy, Rolfo, Christian, Deschoolmeester, Vanessa, Pauwels, Patrick
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Ivyspring International Publisher 2017
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5560132/ https://www.ncbi.nlm.nih.gov/pubmed/28819417 http://dx.doi.org/10.7150/jca.19254

Ejemplares similares

The MDM2-inhibitor Nutlin-3 synergizes with cisplatin to induce p53 dependent tumor cell apoptosis in non-small cell lung cancer
por: Deben, Christophe, et al.
Publicado: (2015)

MDM2 promoter SNP285 and SNP309; phylogeny and impact on cancer risk
por: Knappskog, Stian, et al.
Publicado: (2011)

Hypoxia-Induced Cisplatin Resistance in Non-Small Cell Lung Cancer Cells Is Mediated by HIF-1α and Mutant p53 and Can Be Overcome by Induction of Oxidative Stress
por: Deben, Christophe, et al.
Publicado: (2018)

Effect of the MDM2 promoter polymorphisms SNP309T>G and SNP285G>C on the risk of ovarian cancer in BRCA1 mutation carriers
por: Bjørnslett, Merete, et al.
Publicado: (2012)

Towards Prognostic Profiling of Non-Small Cell Lung Cancer: New Perspectives on the Relevance of Polo-Like Kinase 1 Expression, the TP53 Mutation Status and Hypoxia
por: Van den Bossche, Jolien, et al.
Publicado: (2017)

Population distribution and ancestry of the cancer protective MDM2 SNP285 (rs117039649)
por: Knappskog, Stian, et al.
Publicado: (2014)

Prognostic Impact of the MDM2(SNP309) Allele in Leukemia and Lymphoma
por: Post, Sean M., et al.
Publicado: (2010)

MDM2 SNP309 polymorphism is associated with colorectal cancer risk
por: Wang, Weizhi, et al.
Publicado: (2014)

Association of the MDM2 SNP285 and SNP309 Genetic Variants with the Risk, Age at Onset and Prognosis of Breast Cancer in Central European Women: A Hospital-Based Case-Control Study
por: Miedl, Heidi, et al.
Publicado: (2019)

Unlocking the potential of CD70 as a novel immunotherapeutic target for non-small cell lung cancer
por: Jacobs, Julie, et al.
Publicado: (2015)

Correlations between MDM2 gene SNP309 Polymorphism and Susceptibility to Leukemia
por: Ou, Wen-Bin
Publicado: (2015)

In vitro study of the Polo‐like kinase 1 inhibitor volasertib in non‐small‐cell lung cancer reveals a role for the tumor suppressor p53
por: Van den Bossche, Jolien, et al.
Publicado: (2019)

Association of the MDM2 SNP285 Polymorphism with Cancer Susceptibility: A Meta-Analysis
por: Wang, Ping, et al.
Publicado: (2016)

Preclinical data on the combination of cisplatin and anti-CD70 therapy in non-small cell lung cancer as an excellent match in the era of combination therapy
por: Jacobs, Julie, et al.
Publicado: (2017)

MDM2 SNP309, gene-gene interaction, and tumor susceptibility: an updated meta-analysis
por: Wan, Yan, et al.
Publicado: (2011)

An Updated Meta-Analysis on the Association of MDM2 SNP309 Polymorphism with Colorectal Cancer Risk
por: Qin, Xue, et al.
Publicado: (2013)

Better to be alone than in bad company: The antagonistic effect of cisplatin and crizotinib combination therapy in non-small cell lung cancer
por: Van Der Steen, Nele, et al.
Publicado: (2016)

Simultaneous targeting of EGFR, HER2, and HER4 by afatinib overcomes intrinsic and acquired cetuximab resistance in head and neck squamous cell carcinoma cell lines
por: De Pauw, Ines, et al.
Publicado: (2018)

Rapid Detection of SNP (c.309T>G) in the MDM2 Gene by the Duplex SmartAmp Method
por: Enokida, Yasuaki, et al.
Publicado: (2013)

MDM2 SNP309 rs2279744 Polymorphism and Gastric Cancer Risk: A Meta-Analysis
por: Ma, Yong, et al.
Publicado: (2013)

Impact of TP53 Codon 72 and MDM2 SNP 309 Polymorphisms in Pancreatic Ductal Adenocarcinoma
por: Hori, Yasuki, et al.
Publicado: (2015)

A cohort study on the association of MDM2 SNP309 with lung cancer risk in Bangladeshi population
por: Reza, Hasan Al, et al.
Publicado: (2020)

Mdm2-SNP309 polymorphism in prostate cancer: no evidence for association with increased risk or histopathological tumour characteristics
por: Stoehr, R, et al.
Publicado: (2008)

Influence of the MDM2 single nucleotide polymorphism SNP309 on tumour development in BRCA1 mutation carriers
por: Copson, Ellen R, et al.
Publicado: (2006)

MDM2 SNP309 promoter polymorphism and p53 mutations in urinary bladder carcinoma stage T1
por: Olsson, Hans, et al.
Publicado: (2013)

MDM2 SNP309 polymorphism contributes to endometrial cancer susceptibility: evidence from a meta-analysis
por: Peng, Qiliu, et al.
Publicado: (2013)

Association of MDM2 SNP309 and TP53 Arg72Pro polymorphisms with risk of endometrial cancer
por: YONEDA, TOMOKO, et al.
Publicado: (2013)

Correction: Impact of TP53 Codon 72 and MDM2 SNP 309 Polymorphisms in Pancreatic Ductal Adenocarcinoma
Publicado: (2015)

Association between MDM2 SNP309 and endometrial cancer risk: A PRISMA-compliant meta-analysis
por: Zou, Xinwei, et al.
Publicado: (2018)

Radiosensitization of Non-Small Cell Lung Cancer Cells by the Plk1 Inhibitor Volasertib Is Dependent on the p53 Status
por: Van den Bossche, Jolien, et al.
Publicado: (2019)

Early onset lung cancer, cigarette smoking and the SNP309 of the murine double minute-2 (MDM2) gene
por: Mittelstrass, Kirstin, et al.
Publicado: (2008)

Association of MDM2 SNP309 Variation with Lung Cancer Risk: Evidence from 7196 Cases and 8456 Controls
por: Zhuo, Wenlei, et al.
Publicado: (2012)

MDM2 SNP309 polymorphism is associated with lung cancer risk in women: A meta-analysis using METAGEN
por: HE, WENWU, et al.
Publicado: (2012)

Association of PIK3CA and MDM2 SNP309 with Cervical Squamous Cell Carcinoma in a Philippine Population
por: Tantengco, Ourlad Alzeus G, et al.
Publicado: (2019)

MDM2 SNP309 is associated with high grade node positive breast tumours and is in linkage disequilibrium with a novel MDM2 intron 1 polymorphism
por: Paulin, Fiona EM, et al.
Publicado: (2008)

Overcoming Intrinsic and Acquired Cetuximab Resistance in RAS Wild-Type Colorectal Cancer: An In Vitro Study on the Expression of HER Receptors and the Potential of Afatinib
por: De Pauw, Ines, et al.
Publicado: (2019)

Is MDM2 SNP309 Variation a Risk Factor for Head and Neck Carcinoma?: An Updated Meta-Analysis Based on 11,552 Individuals
por: Zhuo, Xianlu, et al.
Publicado: (2016)

A case‐control study on the SNP309T → G and 40‐bp Del1518 of the MDM2 gene and a systematic review for MDM2 polymorphisms in the patients with breast cancer
por: Jalilvand, Amin, et al.
Publicado: (2020)

Combined effects of single nucleotide polymorphisms TP53 R72P and MDM2 SNP309, and p53 expression on survival of breast cancer patients
por: Schmidt, Marjanka K, et al.
Publicado: (2009)

Immune Checkpoint Modulation in Colorectal Cancer: What's New and What to Expect
por: Jacobs, Julie, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_4986o0ektjh1sl7o0n6h2k7l36